Bristol Myers Squibb FY2025 snapshot
Bristol Myers Squibb reported $48.2B in FY2025 revenue and $7.1B in net income/profit attributable to the company or shareholders. The company has about 32,500 employees and is led by Chris Boerner.
How Bristol Myers Squibb makes money
Bristol Myers Squibb makes money through oncology, hematology, immunology, cardiovascular, neuroscience, cell therapy, and radiopharmaceutical medicines. Bristol Myers Squibb is using legacy cash flows from Eliquis, Opdivo, and hematology brands to fund a pipeline reset in oncology, neuroscience, immunology, cell therapy, and radiopharmaceuticals.
Competitive position
BMS wins through clinical depth, commercial scale in specialty medicines, oncology leadership, and the ability to buy and integrate late-stage assets. The key risk is clear: The biggest risk is patent-cliff execution: generic pressure on legacy brands must be offset by launches such as Cobenfy, Opdivo Qvantig, Reblozyl, Breyanzi, and radiopharmaceutical programs.
